

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN AbobotulinumtoxinA

PRONUNCIATION ab oh bot" ue lye' num tox" in ay

THERAPEUTIC CLAIM Treatment of cervical dystonia and glabellar lines

CHEMICAL NAMES

1. Neurotoxin (*Clostridium botulinum* A strain Hall heavy chain), complex with hemagglutinin (*Clostridium botulinum* A strain Hall) and neurotoxin (*Clostridium botulinum* A strain Hall light chain) and protein NTNH (non-toxin non-hemagglutinin) (*Clostridium botulinum* A strain Hall)
2. Mixture of botulinum neurotoxin type A (BoNT/A, EC 3.4.24.69, Bontoxilysin-A), hemagglutinin component HA33 and botulinum neurotoxin type A1, nontoxic-nonhemagglutinin component, NTNH (EC 3.4.24.69, type A progenitor toxin nontoxic-nonHa), components of the neurotoxin complex (*Clostridium botulinum* A strain Hall)

STRUCTURAL FORMULA

MPFVNKQFN Y KDPVNGVDIA YIKIPNAGQM QPVKAFKIHN KIWVIPERDT
FTNPEEGDLN PPPEAKQVPV SYYDSTYLST DNEKDNYLKG VTKLFEIYIS-100
TDLGRMLLTS IVRGIPFWGG STIDTELKVI DTNCINVIQP DGSYRSEELN
LVIIGPSADI IQFECKSFGH EVLNLTRNGY GSTQYIRFSP DFTFGFEESL-200
EVDTNPLLGA GK FATDPAVT LAHELHAGH RLYGIAINPN RVFKVNTNAY
YEMSGLEVSF EELRTFGGHD AKFIDSLQEN EFRLYYYNKF KDIAS TLNKA-300
KSVIGTTASL QYMKNVFKEK YLLSEDTSGK FSVDKLFKDK LYKMLTEIYT
EDNFVKFFKV LNRKTYLNFD KAVFKINI VP KVN YTIYDGF NLRNTNLAAN-400
FNGQNT EINN MNFTKLNFT GLFEFYKLLC VRGIITSKTK SLDKGYNKAL
NDLCIKVNNW DLFFSPSEDN FTNDLNKGEE ITS DTNIEAA EENISLDLIQ
QYYLTFNFDN EPENISIENL SSDIIGQLEL MPNIERFPNG KKYELDKYTM
FHYLRAQEFE HGKSRIALTN SVNEALLNPS RVYTFSSDY VKKV NKATEA
AMFLGWVEQL VYDFTDETSE VSTTDKIADI TIIPYIGPA LNIGNMLYKD
DFV GALIFSG AVILLEPIPE IAIPVLGTFA LVSYIANKVL TVQTIDNALS
KRNEKWDEVY KYIVTNW LAK VNTQIDLIRK KMKEALENQA EATKAIINYQ
YNQYTEEEKN NINFNIDDL S KLNESINKA MININKFLNQ CSVSYLMNSM
IPYGVKRL ED FDASLKDALL KYIYDNRGTL IGQVDRLKDK VNNTLSTDIP
FQLSKYVDNQ RLLSTFTEYI KNIINTSILN LRYESNHLID LSR YASKINI
GSKVNFDPID KNQIQLFNLE SSKIEVILKN AIVYNSMYEN FSTSFWIRIP
KYFN SISLNN EYTIINC MEN NSGWK VSLNY GEI IWTLQDT QEIKQRV VFK
YSQMINISDY INRWIFVTIT NNRLNNSKIY INGR LIDQKP ISNLGNIHAS
NNIMFKLDGC RDTHRYIWIK YFNLFDKELN EKEIKDLYDN QSN SGILKDF
WGDY LQYDKP YYMLNLYDPN KYVDVNNVGI RGYMYLKGPR GSVMTTNIYL
NSSLYRGTKF IIKKYASGNK DNIVRNDRV YINVVVKNKE YRLATNASQA
GVEKILSALE IPDVG NLSQV VVMKSKNDQG ITNKCKMNLQ DNNGNDIGFI
GFHQFNNAK LVASNWYNRQ IERSSRTLGC SWEFIPVDDG WGERPL

TRADEMARKS Dysport®, Reloxin®, Azzalure®

MANUFACTURER Ipsen Biopharm Limited

CODE DESIGNATION CNT52120

CAS REGISTRY NUMBER 953397-35-8